Enhanced CAR T-cell therapy shows promise in first-in-human trial

· Science · United States

Results from a Phase I clinical trial led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute show a possible way to improve treatment options for patients with relapsed or treatment-resistant B-cell blood cancers. The enhanced CAR T-cell therapy was tested in a first-in-human trial and showed early promise, according to the findings. CAR T-cell therapy reprograms a patient's immune cells to attack cancer, and it has already transformed care for some blood cancers, but many patients relapse or fail to respond. The new approach aims to address those limitations. Early-stage results such as these are watched closely because they can set the direction for larger trials and for future cell-therapy design.

Why it matters：CAR T-cell therapy has transformed some blood cancers but relapse remains common; an enhanced construct that performs well in a first-in-human trial could shape the next generation of cell therapies and their clinical trials.

Key points

  • The trial is a Phase I, first-in-human study for B-cell blood cancers.
  • It targets patients with relapsed or treatment-resistant disease.
  • The findings were led by OSUCCC—James.

Sources (original reporting)

More stories from this day